{"prompt": "['10. Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with', 'the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the', \"patient's safe participation in and completion of the study or interpretation of the study results\", '11. Receipt of:', 'Emicizumab in a prior investigational study', 'An investigational drug to treat or reduce the risk of hemophilic bleeds within five half-lives of', 'last drug administration', 'A non-hemophilia-related investigational drug within last 30 days or five half-lives, whichever', 'is shorter', 'Any concurrent investigational drug.', '12. Pregnancy or lactation, or intent to become pregnant during the study', '13. Positive serum pregnancy test result within 7 days prior to initiation of emicizumab (females only)', 'End of Study and Length of Study', 'The approximate length of the entire study from the first patient enrolled to the last patient, last visit', '(LPLV; see below) is approximately 3 years. For each individual patient, the study is expected to last', 'approximately 2 years (patients will receive 3 mg/kg/week emicizumab for the first 4 weeks followed', 'by 1.5 mg/kg/week emicizumab for the remainder of the 2-year treatment period). Patients who', 'discontinue emicizumab prior to the completion of the 2-year treatment period will undergo a Safety Follow-up', \"Visit 24 weeks after the patient's last emicizumab dose or at 2 years after emicizumab treatment start,\", 'whichever occurs first.', 'The end of this study is defined as the date when the last remaining patient has completed the last', 'visit (i.e., LPLV). The study will end when all patients have been treated with emicizumab for 2 years,', 'or earlier, if one of the following is documented:', 'Withdrawal of consent', 'OR', 'Completed the Safety Follow-up Visit 24 weeks after discontinuing emicizumab', 'OR', 'Lost to follow-up', 'OR', 'Death.', 'Investigational Medicinal Products', 'Test Product (Investigational Drug)', 'Emicizumab will be administered at a dose of 3 mg/kg/week subcutaneously for 4 weeks when', 'initiating treatment, followed by 1.5 mg/kg/week subcutaneously for the remainder of the 2-year', 'treatment period. There will be an option to increase the dose to 3 mg/kg/week in cases of insufficient', 'control of bleeds on the 1.5 mg/kg/week emicizumab dose. If the investigator believes that a specific', 'patient warrants dose up-titration following the occurrence of, for example, at least two spontaneous', 'bleeds, significant bleeds, or a traumatic bleed out of proportion to the degree of injury, they must', 'discuss the case with the Medical Monitor for consideration and potential approval.', 'To support home administration of the drug, patients/caregivers will be required to complete in-person,', 'instructional training on how to administer emicizumab as a subcutaneous (SC) injection.', 'Patients/caregivers will be taught to perform the injections utilizing the Instructions for Use document.', 'In addition, the healthcare provider (HCP) is to inform the patient/caregiver of the volumetric dose to be', 'administered and the dosing frequency. The patients/caregivers will observe at least one SC injection', 'performed by a HCP and will need to successfully administer at least one SC injection under an', \"HCP's supervision prior to starting home administration. The patient/caregiver will also have the\", 'opportunity to ask any questions to the HCP before starting home administration. The first three weekly', 'treatments will be administered in a monitored setting, such as an infusion center, clinic, or hospital, in', 'conjunction with emicizumab PK and pharmacodynamic (PD) assessments. Patients will be observed', 'Emicizumab - F. Hoffmann-La Roche Ltd', '81 / Protocol MO39129, Version 3']['for a minimum of 60 minutes after the first three doses. Patients/caregivers will be instructed on how', 'to recognize signs/symptoms of hypersensitivity (including anaphylaxis) and obtain emergency care in', 'the event of such reactions occurring. Each site will have the discretion to provide additional training', 'or include additional observation (e.g., after the third or fifth doses), if deemed appropriate. If, despite', 'additional training, the investigator determines that the patient/caregiver is unable to inject', 'emicizumab, a trained and proficient caregiver or HCP should be identified to administer the SC', 'injections. Patients/caregivers will be provided with contact information for the clinic in case they have', 'questions related to self-administration between visits.', 'Compliance in the home setting is to be monitored at each site by reviewing reported hemophilia', 'medication use and recording collected used and unused vials.', 'Statistical Methods', 'Primary Safety Analyses', 'The primary objective of this study is to evaluate the overall safety and tolerability of prophylactic', 'administration of emicizumab in patients with congenital hemophilia A who have persistent inhibitors', 'against FVIII at enrollment. Of primary interest in this study are the incidence and severity of all', 'adverse events, including thromboembolic events, microangiopathic hemolytic anemia or TMA, systemic', 'hypersensitivity, anaphylaxis, and anaphylactoid events.', 'All adverse events will be assessed according to the World Health Organization (WHO) toxicity', 'grading scale. The incidence, type, and grade of adverse events will be summarized according to the', 'primary system-organ class (SOC) and, within each SOC, by Medical Dictionary for Regulatory', 'Activities (MedDRA) preferred term. For each adverse event, data will be provided on the timing (start', 'and stop date, time of onset in comparison with last dose of emicizumab received, and doses of', 'emicizumab received), severity, relationship to emicizumab, outcome, and effect on therapy. The data', 'may be presented together with two-sided 95% Clopper-Pearson confidence intervals (CIs) if', 'appropriate.', 'In addition, as part of the safety evaluation, additional assessments will be summarized descriptively', 'as follows:', '1. Cumulative emicizumab doses, dose modifications (delays and interruptions), and duration of', 'exposure', '2. Compliance with respect to emicizumab intake (planned vs. received)', '3. Changes from baseline in physical examination findings', '4. Vital signs over time:', 'Vital signs will be analyzed using descriptive statistics for continuous variables and presented', 'graphically over time with associated 95% Cls.', '5. Laboratory parameters (hematology and chemistry):', 'These parameters will be presented in shift tables of WHO toxicity grade at baseline versus', 'worst grade during the treatment period. Selected laboratory parameters will be summarized', 'in terms of mean, standard deviation, minimum, and maximum. Laboratory parameters will', 'also be presented graphically over time.', 'All safety variables will be analyzed for the safety population. For each variable, the number of', 'available observations will be reported. The safety population includes all patients who have received', 'at least one dose of emicizumab.', 'The primary safety analysis will occur at the end of the study.', 'The iDMC will evaluate the study data, including the emerging safety results, at periodic reviews and', 'recommend to the Sponsor whether the protocol should be amended or the study should be stopped early. All', 'summaries and analyses will be prepared by the Study Management Team (SMT) statistician and presented for', 'iDMC review. Members of the iDMC will be external to the Sponsor and will follow a charter that outlines', 'their roles and responsibilities.', 'A detailed description of the statistical methods that will be used for the primary and secondary', 'analyses will be provided in the Statistical Analysis Plan (SAP).', 'Emicizumab - F. Hoffmann-La Roche Ltd', '82 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}